Caribou Biosciences to Participate in Upcoming Investor Conferences
29 août 2023 16h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
08 août 2023 16h00 HE
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1...
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
13 juil. 2023 23h15 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the pricing of...
Caribou Biosciences Announces Proposed Public Offering of Common Stock
13 juil. 2023 16h03 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced it has...
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
13 juil. 2023 16h01 HE
|
Caribou Biosciences, Inc.
-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR)...
Caribou Biosciences Announces $25 Million Equity Investment from Pfizer
06 juil. 2023 08h00 HE
|
Caribou Biosciences, Inc.
-- Pfizer purchases $25 million of Caribou common shares -- -- Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfizer Global Product Development, has joined Caribou’s...
Caribou Biosciences to Participate in Upcoming Investor Conferences
31 mai 2023 16h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
09 mai 2023 16h00 HE
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients...
Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board
08 mai 2023 09h00 HE
|
Caribou Biosciences, Inc.
-- Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development -- BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a...
Caribou Biosciences to Participate in Upcoming Investor Conferences
01 mai 2023 16h00 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...